Avrobio News

AVROBIO's Strategic Ambiguity: A Commitment to Analysis With Uncertain Outcomes for Shareholders

TipRanksMar 16 02:01 ET

Avrobio (AVRO) Gets a Buy From Wells Fargo

TipRanksMar 15 06:47 ET

Avrobio Buy Rating: Undervalued Merger Potential With Tectonic and Promising Fc-relaxin Asset for G2PH

TipRanksJan 31 05:50 ET

Mizuho Downgrades Avrobio to Neutral, Lowers Price Target to $2

BenzingaDec 18, 2023 11:36 ET

Avrobio Analyst Ratings

BenzingaDec 18, 2023 11:34 ET

Potential Growth and Strategic Alternatives: Reasons Behind Zhu's Buy Rating for Avrobio

TipRanksNov 13, 2023 05:39 ET

Avrobio (AVRO) Gets a Buy From Barclays

TipRanksAug 11, 2023 04:35 ET

Wells Fargo Maintains Overweight on Avrobio, Lowers Price Target to $2

BenzingaJul 13, 2023 07:56 ET

Avrobio Analyst Ratings

BenzingaJul 13, 2023 07:53 ET

Wedbush Downgrades Avrobio to Neutral, Announces $2 Price Target

BenzingaJul 12, 2023 11:40 ET

Avrobio Analyst Ratings

BenzingaJul 12, 2023 11:38 ET

Mizuho Securities Reaffirms Their Buy Rating on Avrobio (AVRO)

TipRanksMay 22, 2023 13:25 ET

Mizuho Securities Keeps Their Buy Rating on Avrobio (AVRO)

TipRanksMay 18, 2023 13:15 ET

Analysts Offer Insights on Healthcare Companies: Avrobio (AVRO), Amylyx Pharmaceuticals Inc (AMLX) and Alcon (ALC)

TipRanksMay 11, 2023 21:40 ET

Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX) and Avrobio (AVRO)

TipRanksMay 1, 2023 12:08 ET

Analysts Offer Insights on Healthcare Companies: Alpine Immune Sciences (ALPN), Avrobio (AVRO) and Omega Therapeutics (OMGA)

TipRanksMar 24, 2023 08:26 ET

Mizuho Adjusts Price Target on AVROBIO to $5 From $6, Keeps Buy Rating

MT NewswiresMar 24, 2023 08:25 ET

Morgan Stanley Sticks to Their Hold Rating for Avrobio (AVRO)

TipRanksMar 24, 2023 06:31 ET

Mizuho Securities Keeps Their Buy Rating on Avrobio (AVRO)

TipRanksMar 23, 2023 21:36 ET

BTIG Upgrades Avrobio to Buy, Announces $4 Price Target

Benzinga Real-time NewsDec 8, 2022 05:23 ET